Preclinical model drawbacks dampen UK innovation, ABPI report says
Preclinical model drawbacks dampen UK innovation, ABPI report says
Publish Date: 2026-02-13 10:42:00
Source Domain: www.pharmaceutical-technology.com
The ABPI has created a framework to effectively prepare compliant academic-produced preclinical models for use in the pharma sector. Image credit: Nadezhda Buravleva via ShutterStock.com.
A report from the Association of the British Pharmaceutical Industry (ABPI) has suggested that a disharmony between academia and industry at the preclinical stage is a key factor stifling UK innovation.
According to the trade body, while early-stage R&D is one of the UK’s strong suits, many preclinical models developed in the country are experiencing a ‘translational readiness gap’. This means that preclinical models developed within academia are not always able to match the requirements of pharmaceutical companies – primarily due to validation, standardisation and scalability hurdles.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Find out more
This is significant, as preclinical models are a strong indicator of how a therapy may perform during clinical trials. If a model is inaccurate, it can lead companies to pursue the development of an ineffective drug, which costs time, money and resources.
Currently, the ABPI estimates that only 10% of medicines make it to market, with the insufficient predictive power of preclinical models remaining a significant driver of attrition during the drug development process.
Addressing preclinical model development challenges
To overcome this…
